Moderna (MRNA) Net Cash Flow (2018 - 2026)
Moderna (MRNA) has disclosed Net Cash Flow for 9 consecutive years, with -$689.0 million as the latest value for Q1 2026.
- For Q1 2026, Net Cash Flow fell 127.39% year-over-year to -$689.0 million; the TTM value through Mar 2026 reached $280.0 million, up 162.92%, while the annual FY2025 figure was $666.0 million, 166.67% up from the prior year.
- Net Cash Flow hit -$689.0 million in Q1 2026 for Moderna, down from $1.5 billion in the prior quarter.
- Across five years, Net Cash Flow topped out at $1.5 billion in Q4 2025 and bottomed at -$2.2 billion in Q2 2022.
- Average Net Cash Flow over 5 years is -$291.4 million, with a median of -$148.0 million recorded in 2025.
- Year-over-year, Net Cash Flow plummeted 1450.93% in 2022 and then surged 1232.0% in 2024.
- Moderna's Net Cash Flow stood at $176.0 million in 2022, then crashed by 114.2% to -$25.0 million in 2023, then soared by 1232.0% to $283.0 million in 2024, then skyrocketed by 416.96% to $1.5 billion in 2025, then tumbled by 147.1% to -$689.0 million in 2026.
- According to Business Quant data, Net Cash Flow over the past three periods came in at -$689.0 million, $1.5 billion, and -$148.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.